Neo-Pharma Biotech Co., Ltd.

S101 is a novel, broad-spectrum antiviral candidate being developed to combat a range of global respiratory infections.
In pre-clinical studies, S101 demonstrates exceptional potency: against COVID-19, it achieves complete viral clearance in just three days, requiring only one-fiftieth the dosage of current first-line treatments.
The optimized nebulized aerosol formulation facilitates rapid cellular absorption, leading to a significantly shortened disease course. S101 shows broad-spectrum therapeutic potential against major respiratory viruses, including COVID-19, Respiratory Syncytial Virus (RSV), Influenza A, and Influenza B.

N723 is a small-molecule drug targeting the rare neurodegenerative disorder, Huntington’s Disease (HD). Pre-clinical studies confirm it improves motor function and slows disease progression without organ toxicity. The drug’s key advantage lies in its delivery: using nebulized nasal inhalation and intravenous (IV) injection to avoid the high risks and systemic toxicity associated with current spinal/intracerebral or oral treatments.

TC911 is a novel, mechanism-based compound designed for pancreatic cancer.
Pre-clinical studies demonstrate superior efficacy over current first-line treatments. TC911’s enhanced Pharmacokinetics (PK) overcomes the challenge of low therapeutic blood concentrations associated with older drugs, enabling substantial dosage reduction and demonstrating improved tolerability (stable body weight in mouse models). TC911 is positioned as a highly promising, next-generation therapeutic.

NOVE is a next-generation vitamin A derivative, officially granted INCI (International Nomenclature of Cosmetic Ingredients) registration in 2025, establishing its global identity as a recognized cosmetic ingredient. Its optimized molecular structure offers significantly improved stability, safety, and skin compatibility, positioning NOVE as an innovative new active for advanced dermatology, medical aesthetics, and high-performance skincare applications.